The facility is intended to support MindWalk’s biologics programs, commercial expansion, working capital, and general corporate purposes. The facility carries a fixed annual interest rate of 7.00%, accruing only on amounts drawn, and an initial term of 36 months, extendable by 12 months by agreement. It includes no financial maintenance covenants, warrants, or equity conversion feature and requires no pledge of MindWalk assets. There is no material adverse change condition to closing. MindWalk has no obligation to borrow and may repay amounts drawn without penalty. A one-time 1.00% opening fee applies, with no unused line fee. The term sheet is binding on both parties. MindWalk and Sanabil (Cayman) will negotiate a definitive credit agreement consistent with its terms, with a target closing within 60 days, and MindWalk expects to file the agreement as a material contract exhibit.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.